No data to show
XCNQ
RAMM
Market cap1mUSD
Feb 04, Last price
0.02CAD
Name
Ramm Pharma Corp
Chart & Performance
P/E
—
P/S
0.55
EPS
—
Div Yield, %
—
Shrs. gr., 5y
18.82%
Rev. gr., 5y
-5.00%
Revenues
4m
-14.28%
Net income
-17m
L+113.73%
CFO
-4m
L-8.89%
Profile
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑10 | 2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | |
| Income | |||||||
Revenues | 4,342 -14.28% | 5,065 29.96% | 3,897 -5.31% | ||||
Cost of revenue | 9,880 | 10,743 | 10,600 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (5,538) | (5,678) | (6,703) | ||||
NOPBT Margin | |||||||
Operating Taxes | 8 | 10 | 8 | ||||
Tax Rate | |||||||
NOPAT | (5,546) | (5,688) | (6,711) | ||||
Net income | (16,502) 113.73% | (7,721) -63.16% | (20,960) 194.93% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | (175) | (221) | |||||
BB yield | 0.90% | ||||||
| Debt | |||||||
Debt current | 103 | 225 | 230 | ||||
Long-term debt | 273 | 585 | 1,137 | ||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | (437) | (4,307) | (10,485) | ||||
| Cash flow | |||||||
Cash from operating activities | (3,998) | (4,388) | (5,913) | ||||
CAPEX | (47) | (62) | (168) | ||||
Cash from investing activities | (47) | 127 | (1,152) | ||||
Cash from financing activities | (258) | (410) | (354) | ||||
FCF | 3,720 | (4,170) | (7,721) | ||||
| Balance | |||||||
Cash | 814 | 5,117 | 9,773 | ||||
Long term investments | 2,079 | ||||||
Excess cash | 597 | 4,864 | 11,658 | ||||
Stockholders' equity | 2,020 | 26,418 | 24,154 | ||||
Invested Capital | 13,226 | 25,006 | 24,605 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 119,389 | 121,036 | 122,773 | ||||
Price | 0.01 | 0.20 -56.99% | |||||
Market cap | 1,194 | 24,555 -51.31% | |||||
EV | 756 | 14,069 | |||||
EBITDA | (4,331) | (4,341) | (5,682) | ||||
EV/EBITDA | |||||||
Interest | 44 | 72 | 13 | ||||
Interest/NOPBT | |||||||